Vaxcyte Inc Ordinary Shares PCVX
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
-
Vaxcyte to Present at the 2024 Cantor Global Healthcare Conference
-
Vaxcyte Announces Closing of $1.5 Billion Public Offering Including Full Exercise of Underwriters’ Option to Purchase Additional Shares
-
Vaxcyte's stock flat as biotech preps to complete $1.42 billion stock offering
-
Vaxcyte Announces Pricing of $1.3 Billion Public Offering
-
Vaxcyte Announces Commencement of Proposed Public Offering of Common Stock and Pre-Funded Warrants
-
Vaxcyte's stock soars 42% to record high after trial shows positive data for pneumococcal vaccine
-
Vaxcyte Reports Positive Topline Data from Phase 1/2 Study of VAX-31, its 31-Valent Pneumococcal Conjugate Vaccine Candidate, in Adults Aged 50 and Older
-
Vaxcyte to Host Webcast and Conference Call to Present Topline Results from Phase 1/2 Study of VAX-31, its 31-Valent Pneumococcal Conjugate Vaccine Candidate, in Adults Aged 50 and Older
Trading Information
- Previous Close Price
- $111.08
- Day Range
- $110.77–112.84
- 52-Week Range
- $44.20–121.06
- Bid/Ask
- $110.79 / $121.98
- Market Cap
- $13.78 Bil
- Volume/Avg
- 502,858 / 963,761
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Total Yield
- —
Company Profile
Vaxcyte Inc is a vaccine company seeking to improve global health by developing novel vaccines to treat patients suffering from the most common and deadly diseases. Its product comprises. of Pneumococcal conjugate vaccine. The firm's product candidate consists of VAX-24, VAX-A1, and VAX-PG.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Mid Growth
- Total Number of Employees
- 254
- Website
- https://www.vaxcyte.com
Comparables
Valuation
|
Metric
|
PCVX
|
NYKD
|
ACLX
|
|---|---|---|---|
Price/Earnings (Normalized) | — | — | — |
Price/Book Value | 6.20 | 0.95 | 8.61 |
Price/Sales | — | 24.14 | 27.51 |
Price/Cash Flow | — | — | 507.02 |
Price/Earnings
PCVX
NYKD
ACLX
Financial Strength
|
Metric
|
PCVX
|
NYKD
|
ACLX
|
|---|---|---|---|
Quick Ratio | 17.75 | 9.28 | 5.85 |
Current Ratio | 17.88 | 9.28 | 6.01 |
Interest Coverage | — | — | −28.35 |
Quick Ratio
PCVX
NYKD
ACLX
Profitability
|
Metric
|
PCVX
|
NYKD
|
ACLX
|
|---|---|---|---|
Return on Assets (Normalized) | −20.76% | −17.82% | −1.88% |
Return on Equity (Normalized) | −22.15% | −22.35% | −3.31% |
Return on Invested Capital (Normalized) | −26.84% | −25.52% | −7.10% |
Return on Assets
PCVX
NYKD
ACLX
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Novo Nordisk AS ADR
NVO
| Fnmtrzmps | Mjq | $512.4 Bil | |||
| Vertex Pharmaceuticals Inc
VRTX
| Vpjfpvh | Xymwhvx | $117.5 Bil | |||
| Regeneron Pharmaceuticals Inc
REGN
| Mljfpnc | Cgyqfn | $111.6 Bil | |||
| Alnylam Pharmaceuticals Inc
ALNY
| Bzvqsgl | Pqgvlfh | $34.4 Bil | |||
| argenx SE ADR
ARGX
| Tthctsctd | Bfsq | $33.0 Bil | |||
| BioNTech SE ADR
BNTX
| Kbtzzlz | Xjckz | $29.2 Bil | |||
| Moderna Inc
MRNA
| Jyvsslg | Xldwm | $23.1 Bil | |||
| United Therapeutics Corp
UTHR
| Bzdsgtjj | Ptz | $15.8 Bil | |||
| Biomarin Pharmaceutical Inc
BMRN
| Bmrtsxn | Dfmtbsm | $13.2 Bil | |||
| Incyte Corp
INCY
| Wvzzxpm | Kxdvldt | $13.0 Bil |
United States